Breaking News Instant updates and real-time market news.

ARDX

Ardelyx

$5.71

-0.08 (-1.38%)

15:40
09/12/19
09/12
15:40
09/12/19
15:40

Ardelyx trading resumes

  • 12

    Sep

  • 16

    Sep

ARDX Ardelyx
$5.71

-0.08 (-1.38%)

04/08/19
04/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ardelyx (ARDX) initiated with an Overweight at Piper Jaffray. 2. Parker Drilling (PKD) initiated with an Outperform at Imperial Capital. 3. Frontdoor (FTDR) initiated with a Buy at Guggenheim. 4. Barnes & Noble Education (BNED) initiated with a Buy at Needham. 5. PlayAGS (AGS) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/03/19
PIPR
09/03/19
NO CHANGE
Target $15
PIPR
Overweight
Ardelyx trial results a 'home run,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he is incrementally positive on Ardelyx and expects the shares to move up "sharply" after the company reported top-line data on lead drug tenapanor's AMPLIFY trial. The "home run" trial results showed that not only can adding tenapanor to a binder lower serum phosphorus significantly, it can do so relatively safely, said Raymond, who expects results from tenapanor's second Phase 3 pivotal trial by year-end and an NDA submission early next year. He keeps an Overweight rating and $15 price target on Ardelyx shares, which are up 15% to $3.92 in early trading.
09/09/19
PIPR
09/09/19
NO CHANGE
Target $15
PIPR
Overweight
Piper still sees 'substantial upside' in Ardelyx despite last week's rally
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations, the market still hasn't grasped tenapanor's full market potential in the renal setting, Raymond tells investors in a research note. Feedback from a recent nephrologist survey indicates "significant" awareness, interest and willingness to prescribe tenapanor, adds the analyst. He sees the drug's revenue potential "at well" over $1B in the U.S. alone. As such, Raymond continues to view his $15 target as a "more appropriate valuation" than current share levels. He maintains an Overweight rating on Ardelyx.
09/12/19
PIPR
09/12/19
NO CHANGE
Target $15
PIPR
Overweight
Piper says Ardelyx IBS-C nod de-risks 'real value driver' of hyperphosphatemia
After Ardelyx announced that the FDA has approved Ibsrela for the treatment of irritable bowel syndrome with constipation, or IBS-C, Piper Jaffray analyst Christopher Raymond said he does not model any value from this indication, but he sees the approval "materially de-risking" approval for hyperphosphatemia, which he views as the "real value driver" for Ardelyx. The analyst, who still sees a significant disconnect between tenapanor's potential in the renal space and the market's current view, despite the stock's 114% quarter-to-date advance, keeps an Overweight rating on Ardelyx shares with a $15 price target.

TODAY'S FREE FLY STORIES

ARQL

ArQule

$8.97

0.32 (3.70%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Initiation
ArQule initiated  »

ArQule initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Breaking Earnings news story on Sonoco »

Sonoco sees Q4 base EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:47
10/17/19
10/17
06:47
10/17/19
06:47
Earnings
Sonoco reports Q3 base EPS 97c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BWXT

BWX Technologies

$56.09

-0.33 (-0.58%)

06:46
10/17/19
10/17
06:46
10/17/19
06:46
Hot Stocks
BWX Technologies awarded $806M contract from U.S. Navy »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Recommendations
Netflix analyst commentary  »

SunTrust incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AAPL

Apple

$234.59

-0.67 (-0.28%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Periodicals
EU examining Apple Pay for antitrust concerns, FT reports »

Apple's Apple Pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ALV

Autoliv

$80.64

0.93 (1.17%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Upgrade
Autoliv rating change  »

Autoliv upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$255.02

-19.58 (-7.13%)

06:44
10/17/19
10/17
06:44
10/17/19
06:44
Recommendations
ServiceNow analyst commentary  »

ServiceNow selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:43
10/17/19
10/17
06:43
10/17/19
06:43
Periodicals
We Company forms committee to consider financing lifeline, Reuters reports »

The We Company (WE) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

JPM

JPMorgan

$119.70

-0.25 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 14

    Jan

CDXC

ChromaDex

$3.41

0.41 (13.67%)

06:41
10/17/19
10/17
06:41
10/17/19
06:41
Hot Stocks
ChromaDex reports new study on nicotinamide riboside importance »

ChromaDex announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$55.47

0.46 (0.84%)

06:39
10/17/19
10/17
06:39
10/17/19
06:39
Downgrade
Brunswick rating change  »

Longbow downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MTB

M&T Bank

$159.14

0.27 (0.17%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Earnings
M&T Bank reports Q3 EPS $3.47, consensus $3.57 »

Reports Q3 common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NEPT

Neptune Wellness

$3.49

0.03 (0.87%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Neptune Wellness to provide extraction services to farming services operation »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSRGY

Nestle

$0.00

(0.00%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Nestle says portfolio management 'fully on track' »

Nestle notes that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNA

Snap-On

$157.68

-0.64 (-0.40%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Hot Stocks
Snap-On sees 2019 CapEx $95M-$105M »

Sees 2019 effective…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle backs underlying FY19 EPS in constant currency up vs. last year »

Full-year guidance for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle reports nine month sales CHF68.367B vs. CHF66.424B last year »

Organic growth reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:35
10/17/19
10/17
06:35
10/17/19
06:35
Earnings
KeyCorp reports Q3 ex-items EPS 48c, consensus 46c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HON

Honeywell

$163.86

0.2 (0.12%)

06:35
10/17/19
10/17
06:35
10/17/19
06:35
Earnings
Honeywell narrows FY19 EPS view to $8.10-$8.15 from $7.95-$8.15, consensus $8.09 »

Narrows FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:34
10/17/19
10/17
06:34
10/17/19
06:34
Hot Stocks
Nestle to distribute CHF20B to shareholders via share buybacks »

Nestle's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$3.07

0.335 (12.27%)

, NSRGY

Nestle

$0.00

(0.00%)

06:34
10/17/19
10/17
06:34
10/17/19
06:34
Hot Stocks
New Age Beverages partners with Nestle to relaunch NESTEA in U.S. »

New Age Beverages (NBEV)…

NBEV

New Age Beverages

$3.07

0.335 (12.27%)

NSRGY

Nestle

$0.00

(0.00%)

KO

Coca-Cola

$53.49

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Hot Stocks
Breaking Hot Stocks news story on TSMC »

TSMC sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Earnings
TSMC sees Q4 revenue $10.2B-$10.3B, consensus $9.63B »

Gross profit margin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HON

Honeywell

$163.86

0.2 (0.12%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Earnings
Honeywell reports Q3 adj. EPS $2.08, consensus $2.01 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:32
10/17/19
10/17
06:32
10/17/19
06:32
Earnings
TSMC reports Q3 EPS 62c, consensus 60c »

Reports Q3 revenue $9.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.